External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology Tucson Symposium 2025
Roche and Genentech at

Tucson Symposium 2025

April 01 - April 02
Arizona, USA
diagnostics.roche.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
03:00 PM
Duration 60mins Arizona, USA
AVENIO Tumor Tissue CGP Automated Assay: End-to-End Solution with High Sample Pass Rate, and High Analytical Sensitivity and Specificity
Megan Fong
Oncology | Tumor tissue

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Arizona, USA
AVENIO Tumor Tissue CGP Automated Assay: End-to-End Solution With High Performance on NextSeq 500/550
Vivian Yu
Oncology | Tumor tissue

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Arizona, USA
ctDNA-Based MRD Assay for Non-Hodgkin Lymphomas: Applications for Risk Stratification and Disease Monitoring
Corinna Lutterbeck
Oncology | Non-Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Arizona, USA
Roche Digital Pathology Dx whole slide imaging system is comparable to traditional microscopy for primary diagnosis in surgical pathology
Keith A. Wharton
Oncology | Tumor tissue

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Arizona, USA
Evaluation of pre analytics and the impact on staining with the ultrasensitive kappa and lambda Dual ISH Assay
Bowdoin Su
Oncology | B Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Arizona, USA
Digital and glass slide reads with ultrasensitive kappa and lambda dual ISH in situ hybridization mRNA assay show high first pass rates and concordances with flow cytometry in the assessment of restriction status in B cell lymphomas and plasma cell neoplasms
Bowdoin Su
Oncology | B Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Arizona, USA
An ultrasensitive dual in situ hybridization (ISH) mRNA assay is equivalent in performance to flow cytometry in determination of kappa/lambda (K/L) restriction status in B cell lymphomas and plasma cell malignancies
Sarah Gladden
Oncology | B Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Arizona, USA
Evaluating Navify Mutation Profiler for Use in Tertiary Analysis of Hematologic Malignancies
Michael Clark
Oncology | B Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.